The arrival of Retatrutide ZPHC, at a strength of 120mg, is sparking considerable excitement within the weight loss community. This novel dual GIP and GLP-1 target medication suggests to provide impressive improvements in weight loss compared to existing therapies. Preliminary patient trials have shown marked decreases in weight , possibly marking